Literature DB >> 17548610

Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.

Jooeun Bae1, Constantine Mitsiades, Yu-Tzu Tai, Robert Bertheau, Masood Shammas, Ramesh Babu Batchu, Cheng Li, Lawrence Catley, Rao Prabhala, Kenneth C Anderson, Nikhil C Munshi.   

Abstract

The 90-kDa heat shock protein (Hsp90) plays an important role in conformational regulation of cellular proteins and thereby cellular signaling and function. As Hsp90 is considered a key component of immune function and its inhibition has become an important target for cancer therapy, we here evaluated the role of Hsp90 in human dendritic cell (DC) phenotype and function. Hsp90 inhibition significantly decreased cell surface expression of costimulatory (CD40, CD80, CD86), maturation (CD83), and MHC (HLA-A, B, C and HLA-DP, DQ, DR) markers in immature DC and mature DC and was associated with down-regulation of both RNA and intracellular protein expression. Importantly, Hsp90 inhibition significantly inhibited DC function. It decreased Ag uptake, processing, and presentation by immature DC, leading to reduced T cell proliferation in response to tetanus toxoid as a recall Ag. It also decreased the ability of mature DC to present Ag to T cells and secrete IL-12 as well as induce IFN-gamma secretion by allogeneic T cells. These data therefore demonstrate that Hsp90-mediated protein folding is required for DC function and, conversely, Hsp90 inhibition disrupts the DC function of significant relevance in the setting of clinical trials evaluating novel Hsp90 inhibitor therapy in cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548610     DOI: 10.4049/jimmunol.178.12.7730

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells.

Authors:  Josetta L Houlihan; Jennifer J Metzler; Janice S Blum
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

2.  Dynamic duo takes down fungal villains.

Authors:  Camile P Semighini; Joseph Heitman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-26       Impact factor: 11.205

3.  Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.

Authors:  Jooeun Bae; Aditya Munshi; Cheng Li; Mehmet Samur; Rao Prabhala; Constantine Mitsiades; Kenneth C Anderson; Nikhil C Munshi
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

4.  Incubation of whole blood at 39°C augments gamma interferon (IFN-γ)-induced protein 10 and IFN-γ responses to Mycobacterium tuberculosis antigens.

Authors:  Martine G Aabye; Pernille Ravn; Isik S Johansen; Jesper Eugen-Olsen; Morten Ruhwald
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

Review 5.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.

Authors:  Qingrong Huang; Shan He; Yuanyuan Tian; Yuting Gu; Pan Chen; Changhong Li; Jiefang Huang; Yongnian Liu; Hongshuang Yu; Min Jin; Shaoyan Hu; Qing Tong; Anqi Ma; Jian Jin; Elizabeth Hexner; Henry Fung; Ran Reshef; Yi Zhang; Yanyun Zhang
Journal:  Blood       Date:  2017-02-28       Impact factor: 22.113

7.  Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90.

Authors:  B Zunino; C Rubio-Patiño; E Villa; O Meynet; E Proics; A Cornille; S Pommier; L Mondragón; J Chiche; J-M Bereder; M Carles; J-E Ricci
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

8.  Hsp90 inhibition: elimination of shock and stress.

Authors:  Adam S Duerfeldt; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2010-07-01       Impact factor: 2.823

9.  Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.

Authors:  Aparna Rao; Jennifer L Taylor; Nina Chi-Sabins; Mayumi Kawabe; William E Gooding; Walter J Storkus
Journal:  Cancer Res       Date:  2012-05-02       Impact factor: 12.701

Review 10.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.